CRON vs CURLF vs ACB Stock Comparison

Cronos, Curaleaf Holdings and Aurora Cannabis Prices as of Nov 13, 2026 Peers: Industry group
CRON Cronos Group Inc.
$3.38 +7.0% 1M +36.3% 1Y
Market cap
$1.21B
P/E
21.0x
Revenue (TTM)
$271.85M
Div. yield
–
Cannabis Consumer Staples
8 wins
ACB Aurora Cannabis Inc
$4.94 +18.5% 1M +12.5% 1Y
Market cap
$258.05M
P/E
24.7x
Revenue (TTM)
$205.55M
Div. yield
–
Cannabis Consumer Staples
1 win

Head to Head

11 decided of 12

Cronos leads on 8 of the 12 questions below (Cronos 8, Curaleaf Holdings 2, Aurora Cannabis 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCRONCURLFACBLeader
Larger companyMarket capitalisation $1.21B $2.08B $258.05M CURLF
Cheaper on earningsLower P/E, profitable companies only 21.0x -203.7x 24.7x CRON
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.9x 98.1x — CRON
Faster revenue growthRevenue growth, trailing twelve months +54.3% +7.3% -13.3% CRON
More profitableNet margin, trailing twelve months 21.3% -0.8% 5.1% CRON
Better return on capitalReturn on invested capital — 0.7% -0.8% CURLF
Less leveragedLower net debt / EBITDA — 2.6x -2.4x ACB
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +36.3% +1.4% +12.5% CRON
Better 5-year returnAnnualised price return, 5 years -11.6%/yr -24.3%/yr -43.4%/yr CRON
Less volatileAnnualised volatility, 1 year 40.0% 100.1% 58.6% CRON
Higher overall scoreMean of the five percentile scores vs peers 88/100 59/100 49/100 CRON

Percentile Scorecard

CRONCURLFACB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCRONCURLFACB
Valuation 68 #13 of 39 45 #22 of 39 47 #21 of 39
Growth 97 #2 of 37 83 #7 of 37 31 #26 of 37
Profitability 81 #8 of 37 67 #13 of 37 47 #20 of 37
Financial Health 100 #1 of 41 43 #24 of 41 95 #3 of 41
Shareholder Returns 94 #2 of 17 56 #8 of 17 25 #13 of 17
Overall 88 59 49
  • CRON ranked among 41 companies in Tobacco and Cannabis
  • CURLF ranked among 41 companies in Tobacco and Cannabis
  • ACB ranked among 41 companies in Tobacco and Cannabis

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCRONCURLFACBSPY
1 month +7.0%-8.0%+18.5% -2.0%
3 months +7.6%-17.2%+34.2% -2.8%
6 months +28.5%-23.3%+48.8% +2.0%
Year to date +28.5%+3.8%+17.1% +10.6%
1 year +36.3%+1.4%+12.5% +12.2%
3 years +69.0%-19.5%+6.0% +68.1%
3 years, per year +19.1%-7.0%+2.0% +18.9%
5 years -46.0%-75.2%-94.2% +61.4%
5 years, per year -11.6%-24.3%-43.4% +10.1%
10 years ——-97.3% +248.5%
10 years, per year ——-30.2% +13.3%

Risk

MeasureCRONCURLFACBSPY
Volatility, 1Y 40.0%100.1%58.6% 13.6%
Downside volatility, 1Y 36.1%96.4%50.6% 13.9%
Beta vs S&P 500, 1Y 0.351.151.02 1.00
Return / volatility, 1Y 0.910.010.21 0.90
Max drawdown, 5Y -72.7%-92.7%-96.9% -25.4%
From 52-week high -9.1%-44.3%-11.3% -3.2%
52-week high $3.72$14.10$5.57 $779.14
52-week low $2.30$5.67$2.58 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCRONCURLFACB
P/E now vs peer median 21.5xmedian 18.9x -203.2xmedian 18.9x 26.8xmedian 18.9x
P/S now vs peer median 4.6xmedian 0.7x 1.5xmedian 0.7x 1.4xmedian 0.7x
EV/EBITDA now vs peer median 22.2xmedian 11.5x 12.6xmedian 11.5x 13.6xmedian 11.5x
P/FCF now vs peer median 19.0xmedian 14.4x 43.0xmedian 14.4x -12.7xmedian 14.4x
P/B now vs peer median 1.1xmedian 0.9x 2.5xmedian 0.9x 0.8xmedian 0.9x
PEG now vs peer median 0.59median 1.00 -3.30median 1.00 1.02median 1.00

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCRONCURLFACB
Revenue $271.85M $1.35B $205.55M
Gross profit $96.08M $659.48M $107.73M
Operating income $7.10M $10.83M -$3.06M
Net income $67.38M -$10.23M -$89.40M
Free cash flow $65.38M $48.38M -$22.85M
R&D $5.35M – $2.98M
EPS (diluted) $0.16 $-0.04 $0.18
Cash & equivalents $411.19M $92.39M $46.43M
Total debt – $629.48M $15.10M
Shares (diluted) 370.72M 264.88M 57.30M
Enterprise value -$1.98B $1.70B -$34.40M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCRONCURLFACB
P/E 21.5x -203.2x 26.8x
P/FCF 19.0x 43.0x -12.7x
P/Operating cash flow 15.3x 18.1x -45.9x
P/S 4.6x 1.5x 1.4x
P/B 1.1x 2.5x 0.8x
P/Tangible book 1.1x -22.2x 0.9x
EV/EBITDA 22.2x 12.6x 13.6x
EV/EBIT 70.6x 241.6x -80.9x
EV/Revenue 1.8x 1.9x 1.2x
EV/FCF 7.7x 54.1x -10.8x
EV/Operating cash flow 6.2x 22.8x -39.0x
PEG (3Y EPS CAGR) 0.59 -3.30 1.02

Growth

14 metrics
MetricCRONCURLFACB
Revenue growth (1Y) 54.3% 7.3% -13.3%
Revenue CAGR (3Y) 33.1% 0.1% 3.6%
Gross profit growth (1Y) 67.4% 5.0% -6.4%
Gross profit CAGR (3Y) 104.4% 4.7% 43.8%
Operating income growth (1Y) 133.4% -39.1% 73.1%
Operating income CAGR (3Y) 27.6% 48.7% 69.4%
Net income growth (1Y) 58.3% 95.8% -434.6%
Net income CAGR (3Y) 37.9% 71.9% 2.2%
EPS growth (1Y) 66.4% 96.1% -63.5%
EPS CAGR (3Y) 36.6% 61.7% 26.3%
Operating cash flow growth (1Y) 272.8% -30.4% -225.7%
Operating cash flow CAGR (3Y) 43.7% 6.6% 60.3%
Free cash flow growth (1Y) 1,317% 221.7% -514.2%
Free cash flow CAGR (3Y) 40.3% 35.9% 36.8%

Profitability

14 metrics
MetricCRONCURLFACB
Gross margin 35.3% 48.8% 52.4%
EBITDA margin 8.3% 15.4% 8.8%
Operating margin 2.6% 0.8% -1.5%
Pretax margin 22.1% -7.6% 1.6%
Net margin 21.3% -0.8% 5.1%
FCF margin 24.0% 3.6% -11.1%
Operating cash flow margin 29.8% 8.5% -3.1%
Return on equity 6.1% -0.9% -17.4%
Return on assets 5.8% -0.3% -14.7%
Return on invested capital – 0.7% -0.8%
Return on capital employed 0.6% 0.4% –
Asset turnover 0.2x 0.5x 0.5x
Cash conversion (OCF / net income) 1.2x -11.2x 0.1x
Stock comp / revenue 2.4% 3.4% 1.6%

Financial Health

11 metrics
MetricCRONCURLFACB
Debt / assets – 22.5% 3.5%
Debt / equity – 0.7x 0.0x
Net debt / EBITDA – 2.6x -2.4x
Debt / FCF – 13.0x -0.7x
Liabilities / assets 6.1% 69.7% 15.7%
Equity / assets 93.9% 30.3% 84.3%
Interest coverage – – -0.8x
Current ratio 12.7x 1.6x –
Quick ratio 11.6x 0.6x –
Cash ratio 11.0x 0.3x –
Altman Z-score 11.79 0.44 –

Shareholder Returns

7 metrics
MetricCRONCURLFACB
Dividend yield – – –
Net buyback yield 3.7% -0.1% -6.9%
Shareholder yield 3.7% -0.1% -6.9%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCRONCURLFACB
Forward P/E 19.9xFY2026 98.1xFY2026 –
EPS, next fiscal year $0.17FY2026 $0.08FY2026 $-0.35FY2026
EPS growth, the year after +11.8% -412.5% –
Revenue, next fiscal year $218.83MFY2026 $1.41BFY2026 $231.08MFY2026
Revenue growth, next FY +49.3%FY2026 +10.9%FY2026 +0.3%FY2026
Revenue growth, the year after +22.5% -0.1% -3.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCRONCURLFACB
Held by institutions 12.8% 0.0% 9.3%
Institutions holding 197 2 152
Change in shares held, QoQ -2.5% -86.3% -1.3%
Institutions buying 71 1 52
Institutions selling 41 1 17
Buyers to sellers 1.73 1.00 3.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CRONCURLFACB
CRON 1.00 0.51 0.55
CURLF 0.51 1.00 0.59
ACB 0.55 0.59 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CRON, CURLF and ACB?

Curaleaf Holdings (CURLF) is the largest by market capitalisation: Cronos (CRON) $1.21B, Curaleaf Holdings (CURLF) $2.08B, Aurora Cannabis (ACB) $258.05M.

Which stock is cheaper, CRON, CURLF and ACB?

Cronos (CRON) trades on the lowest price-to-earnings ratio (Cronos (CRON) 21.0x, Curaleaf Holdings (CURLF) -203.7x, Aurora Cannabis (ACB) 24.7x). On next year's consensus earnings, Cronos (CRON) is cheapest (Cronos (CRON) 19.9x, Curaleaf Holdings (CURLF) 98.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Cronos (CRON) grew revenue fastest over the trailing twelve months: Cronos (CRON) +54.3%, Curaleaf Holdings (CURLF) +7.3%, Aurora Cannabis (ACB) -13.3%.

Which company is more profitable?

Cronos (CRON) has the highest net margin (Cronos (CRON) 21.3%, Curaleaf Holdings (CURLF) -0.8%, Aurora Cannabis (ACB) 5.1%). On return on invested capital, Curaleaf Holdings (CURLF) leads (Curaleaf Holdings (CURLF) 0.7%, Aurora Cannabis (ACB) -0.8%).

Which stock has performed better?

Over the past year Cronos (CRON) returned the most: Cronos (CRON) +36.3%, Curaleaf Holdings (CURLF) +1.4%, Aurora Cannabis (ACB) +12.5%. Over five years, Cronos (CRON) compounded fastest (Cronos (CRON) -11.6%/yr, Curaleaf Holdings (CURLF) -24.3%/yr, Aurora Cannabis (ACB) -43.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Cronos (CRON) has been the steadiest (Cronos (CRON) 40.0%, Curaleaf Holdings (CURLF) 100.1%, Aurora Cannabis (ACB) 58.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CRON, CURLF and ACB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cronos (CRON) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.